{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T22:27:19Z","timestamp":1788560839329,"version":"build-2803163510"},"reference-count":52,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T00:00:00Z","timestamp":1721001600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Epilepsia"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>For &gt;30\u2009years, the Eilat Conference on New Antiepileptic Drugs and Devices has provided a forum for the discussion of advances in the development of new therapies for seizures and epilepsy. The EILAT XVII conference took place in Madrid, Spain, on May 5\u20138, 2024. Participants included basic scientists and clinical investigators from industry and academia, other health care professionals, and representatives from lay organizations. We summarize in this article information on treatments in preclinical and in early clinical development discussed at the conference. These include AMT\u2010260, a gene therapy designed to downregulate the expression of Glu2K subunits of kainate receptors, in development for the treatment of drug\u2010resistant seizures associated with mesial temporal sclerosis; BHV\u20107000, a selective activator of heteromeric Kv7.2\/7.3 potassium channels, in development for the treatment of focal epilepsy; ETX101, a recombinant adeno\u2010associated virus serotype 9 designed to increase Na<jats:sub>V<\/jats:sub>1.1 channel density in inhibitory \u03b3\u2010aminobutyric acidergic (GABAergic) neurons, in development for the treatment of <jats:italic>SCN1A<\/jats:italic>\u2010positive Dravet syndrome; GAO\u20103\u201002, a compound structurally related to synaptamide, which exerts antiseizure activity at least in part through an action on cannabinoid type 2 receptors; LRP\u2010661, a structural analogue of cannabidiol, in development for the treatment of seizures associated with Lennox\u2013Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex; OV329, a selective inactivator of GABA aminotransferase, in development for the treatment of drug\u2010resistant seizures; PRAX\u2010628, a functionally selective potent sodium channel modulator with preference for the hyperexcitable state of sodium channels, in development for the treatment of focal seizures; RAP\u2010219, a selective negative allosteric modulator of transmembrane \u03b1\u2010amino\u20103\u2010hydroxy\u20105\u2010methyl\u20104\u2010isoxazolepropionic acid receptor regulatory protein \u03b3\u20108, in development for the treatment of focal seizures; and rozanolixizumab, a humanized anti\u2010neonatal Fc receptor monoclonal antibody, in development for the treatment of LGI1 autoimmune encephalitis. Treatments in more advanced development are summarized in Part II of this report.<\/jats:p>","DOI":"10.1111\/epi.18056","type":"journal-article","created":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T15:45:32Z","timestamp":1721058332000},"page":"2831-2857","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Progress report on new medications for seizures and epilepsy: A summary of the 17th Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII). I. Drugs in preclinical and early clinical development"],"prefix":"10.1111","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2046-4171","authenticated-orcid":false,"given":"Meir","family":"Bialer","sequence":"first","affiliation":[{"name":"Institute for Drug Research, School of Pharmacy, Faculty of Medicine and David R. Bloom Center for Pharmacy Hebrew University of Jerusalem  Jerusalem Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7087-6655","authenticated-orcid":false,"given":"Svein I.","family":"Johannessen","sequence":"additional","affiliation":[{"name":"National Center for Epilepsy  Sandvika Norway"},{"name":"Member of European Reference Network EpiCARE Oslo University Hospital  Oslo Norway"},{"name":"Section for Clinical Pharmacology, Department of Pharmacology Oslo University Hospital  Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4277-8000","authenticated-orcid":false,"given":"Matthias J.","family":"Koepp","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Epilepsy University College London (UCL), Queen Square Institute of Neurology  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8703-223X","authenticated-orcid":false,"given":"Emilio","family":"Perucca","sequence":"additional","affiliation":[{"name":"Department of Medicine (Austin Health) University of Melbourne  Melbourne Victoria Australia"},{"name":"Department of Neuroscience, School of Translational Medicine Monash University  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7855-7066","authenticated-orcid":false,"given":"Piero","family":"Perucca","sequence":"additional","affiliation":[{"name":"Department of Medicine (Austin Health) University of Melbourne  Melbourne Victoria Australia"},{"name":"Department of Neuroscience, School of Translational Medicine Monash University  Melbourne Victoria Australia"},{"name":"Bladin\u2010Berkovic Comprehensive Epilepsy Program, Department of Neurology Austin Health  Melbourne Victoria Australia"},{"name":"Department of Neurology Royal Melbourne Hospital  Melbourne Victoria Australia"},{"name":"Department of Neurology Alfred Health  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0554-5352","authenticated-orcid":false,"given":"Torbj\u00f6rn","family":"Tomson","sequence":"additional","affiliation":[{"name":"Department of Clinical Neuroscience Karolinska Institute  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4550-4408","authenticated-orcid":false,"given":"H. Steve","family":"White","sequence":"additional","affiliation":[{"name":"Center for Epilepsy Drug Discovery, Department of Pharmacy, School of Pharmacy University of Washington  Seattle Washington USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,7,15]]},"reference":[{"key":"e_1_2_16_2_1","unstructured":"Epilepsy Foundation.Pipeline Conference.2022Available from:https:\/\/www.epilepsy.com\/stories\/2022\u2010pipeline\u2010conference"},{"key":"e_1_2_16_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.17884"},{"key":"e_1_2_16_4_1","doi-asserted-by":"crossref","unstructured":"BialerM JohannessenSI KoeppMJ PeruccaE PeruccaP TomsonT et\u00a0al.Progress report on new antiepileptic drugs: A summary of the Seventeenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII): II. Drugs in more advanced clinical development. Epilepsia 2024 (this issue).","DOI":"10.1111\/epi.18075"},{"key":"e_1_2_16_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2021.07.007"},{"key":"e_1_2_16_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2014.11.012"},{"key":"e_1_2_16_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26723"},{"key":"e_1_2_16_8_1","doi-asserted-by":"crossref","unstructured":"BaudouinS PearsonN PartoucheN WartelM KeskinS MulleC et\u00a0al.Preclinical efficacy and safety assessment of AMT\u2010260 a novel AAV9\u2010dual MicroRNA\u2010based vector targeting GRIK2 for the treatment of temporal lobe epilepsy. Presented at: AES annual meeting.2023Poster 3.259. Available from:https:\/\/aesnet.org\/abstractslisting\/preclinical\u2010efficacy\u2010and\u2010safety\u2010assessment\u2010of\u2010amt\u2010260\u2010a\u2010novel\u2010aav9\u2010dual\u2010microrna\u2010based\u2010vector\u2010targeting\u2010grik2\u2010for\u2010the\u2010treatment\u2010of\u2010temporal\u2010lobe\u2010epilepsy 100","DOI":"10.1212\/WNL.0000000000203971"},{"key":"e_1_2_16_9_1","doi-asserted-by":"crossref","unstructured":"PicchioneK ResnickL BozikM DworetzkyS.Characterization of BHV\u20107000: A Novel Kv7.2\/7.3 Activator for the Treatment of Seizures.2023Presented at American Epilepsy Society Annual Meeting. Orlando FL. Poster 2.249.https:\/\/aesnet.org\/abstractslisting\/characterization\u2010of\u2010bhv\u20107000\u2010a\u2010novel\u2010kv7\u20102\u20107\u20103\u2010activator\u2010for\u2010the\u2010treatment\u2010of\u2010seizures","DOI":"10.1212\/WNL.0000000000206250"},{"key":"e_1_2_16_10_1","unstructured":"LernerJ AwsareB SevinskyE AshbrennerE KillingsworthR KendrickR et\u00a0al.Novel Selective Kv7.2\/7.3 Potassium Channel Activator BHV\u20107000 Demonstrates Dose\u2010Dependent Pharmacodynamic Effects on EEG Parameters in Healthy Adults. Presented at American Epilepsy Society Annual Meeting. Orlando FL. Poster 2.510. Availabable from:https:\/\/aesnet.org\/abstractslisting\/novel\u2010selective\u2010kv7\u20102\u20107\u20103\u2010potassium\u2010channel\u2010activator\u2010bhv\u20107000\u2010demonstrates\u2010dose\u2010dependent\u2010pharmacodynamic\u2010effects\u2010on\u2010eeg\u2010parameters\u2010in\u2010healthy\u2010adults"},{"key":"e_1_2_16_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-05179-x"},{"key":"e_1_2_16_12_1","doi-asserted-by":"crossref","unstructured":"AwsareB LernerJ AshbrennerE SevinskyH BozikM DworetzkyS et\u00a0al.A First in Human Phase 1 Study Evaluating the Safety and Tolerability of BHV\u20107000 a Novel Selective Kv7.2\/7.3 Potassium Channel Activator in Healthy Adults. Presented at American Epilepsy Society Annual Meeting. 2023; Orlando FL. Poster 3.265. Available from:https:\/\/aesnet.org\/abstractslisting\/a\u2010first\u2010in\u2010human\u2010phase\u20101\u2010study\u2010evaluating\u2010the\u2010safety\u2010and\u2010tolerability\u2010of\u2010bhv\u20107000\u2010a\u2010novel\u2010selective\u2010kv7\u20102\u20107\u20103\u2010potassium\u2010channel\u2010activator\u2010in\u2010healthy\u2010adults","DOI":"10.1212\/WNL.0000000000206409"},{"key":"e_1_2_16_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.17850"},{"key":"e_1_2_16_14_1","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2022.037"},{"key":"e_1_2_16_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.17373"},{"key":"e_1_2_16_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/0013-4694(72)90177-0"},{"key":"e_1_2_16_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.16725"},{"key":"e_1_2_16_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13123"},{"key":"e_1_2_16_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbalip.2018.08.003"},{"key":"e_1_2_16_20_1","first-page":"644","article-title":"SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor","volume":"284","author":"Rinaldi\u2010Carmona M","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_16_21_1","doi-asserted-by":"publisher","DOI":"10.1515\/hsz-2019-0270"},{"key":"e_1_2_16_22_1","doi-asserted-by":"publisher","DOI":"10.2131\/jts.31.315"},{"key":"e_1_2_16_23_1","doi-asserted-by":"publisher","DOI":"10.1078\/0940-2993-00338"},{"key":"e_1_2_16_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-2275(20)39826-6"},{"key":"e_1_2_16_25_1","doi-asserted-by":"publisher","DOI":"10.2165\/00137696-200402040-00003"},{"key":"e_1_2_16_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0992-5"},{"key":"e_1_2_16_27_1","unstructured":"SarmierePD RoucardC EvrardA FishbackJ.OV329 a GABA aminotransferase (GABA\u2010AT) Inhibitor suppresses hippocampal paroxysmal discharges in a human translational mesial\u2010temporal love epilepsy (MTLE) mouse model. Annual Meeting of the American Epilepsy society Chicago (abstract).2021Available from:https:\/\/cms.aesnet.org\/abstractslisting\/ov329\u2010\u2010a\u2010gaba\u2010aminotransferase\u2010(gaba\u2010at)\u2010inhibitor\u2010\u2010suppresses\u2010hippocampal\u2010paroxysmal\u2010discharges\u2010in\u2010a\u2010human\u2010translational\u2010mesial\u2010temporal\u2010lobe\u2010epilepsy\u2010(mtle)\u2010mouse\u2010model"},{"key":"e_1_2_16_28_1","unstructured":"SarmierePD ColburnR MukherjeeJ.Evaluation of OV329 a next\u2010generation GABA\u2010AT inhibitor in a series of Pharmaco\u2010resistant seizure models through the NINDS epilepsy therapy screening program. Annual Meeting of the American Epilepsy Society Nashvillem.2022(abstract). Available from:https:\/\/aesnet.org\/abstractslisting\/evaluation\u2010of\u2010OV329\u2010a\u2010next\u2010generation\u2010gaba\u2010at\u2010inhibitor\u2010in\u2010a\u2010series\u2010of\u2010pharmaco\u2010resistant\u2010seizure\u2010models\u2010through\u2010the\u2010ninds\u2010epilepsy\u2010therapy\u2010screening\u2010program"},{"key":"e_1_2_16_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.17090"},{"key":"e_1_2_16_30_1","unstructured":"National Institutes of Neurological Disorders and Stroke (NINDS).PANAChE: Public Access to Neuroactive and Anticonvulsant Chemical Evaluations (PANAChE). Available from:https:\/\/panache.ninds.nih.gov\/TestDescription\/TestIAKM"},{"key":"e_1_2_16_31_1","doi-asserted-by":"publisher","DOI":"10.1021\/jacs.7b10965"},{"key":"e_1_2_16_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2021.108517"},{"key":"e_1_2_16_33_1","doi-asserted-by":"crossref","unstructured":"KahligK ChapmanM PetrouS.PRAX\u2010628: A Novel Sodium Channel Blocker with Greater Potency and Activity Dependence Compared to Standard of Care. American Academy of Neurology Meeting; April 22\u201327 2023; Boston Massachussetts.https:\/\/doi.org\/10.1212\/WNL.0000000000203120[poster available for download fromhttps:\/\/praxismedicines.com\/wp\u2010content\/uploads\/2023\/09\/Kahlig_AAN2023_628\u2010In\u2010Vitro_Final_Approved.pdf]","DOI":"10.1212\/WNL.0000000000203120"},{"key":"e_1_2_16_34_1","unstructured":"AndersonL KahligK PetrouS.PRAX\u2010628 is a next generation functionally selective small molecule with potent anti\u2010seizure activity and potential as best\u2010in\u2010class treatment for focal epilepsy. American Epilepsy Society Annual Meeting; December 1\u20135 2023; Orlando Florida. Available from:https:\/\/www.aesnet.org\/abstractslisting\/prax\u2010628\u2010is\u2010a\u2010next\u2010generation\u2010functionally\u2010selective\u2010small\u2010molecule\u2010with\u2010potent\u2010anti\u2010seizure\u2010activity\u2010and\u2010potential\u2010as\u2010best\u2010in\u2010class\u2010treatment\u2010for\u2010focal\u2010epilepsy[poster available for download fromhttps:\/\/praxismedicines.com\/wp\u2010content\/uploads\/2023\/12\/Kahlig_AES2023_628\u2010In\u2010Vivo_Poster_Final.pdf]"},{"key":"e_1_2_16_35_1","unstructured":"HansenK PatelD WehrA HardM FrizzoS PetrouS et\u00a0al.Safety tolerability and pharmacokinetic findings from a first\u2010in\u2010human randomized double\u2010blind placebo\u2010controlled trial of single and multiple ascending doses of PRAX\u2010628 in healthy participants. International Epilepsy Congress; September 2\u20136 2023; Dublin Ireland. Available from:https:\/\/iec2023.abstractserver.com\/program\/#\/details\/presentations\/1625[poster available for download fromhttps:\/\/praxismedicines.com\/wp\u2010content\/uploads\/2023\/09\/IEC2023_628\u2010SAD\u2010MAD.pdf]"},{"key":"e_1_2_16_36_1","unstructured":"GarimellaA JasminA HansenK SouzaM.A novel method to define an EEG composite for the detection of drug effects of next generation small molecules for epilepsy. American Epilepsy Society Annual Meeting; December 1\u20135 2023; Orlando Florida. Available from:https:\/\/www.aesnet.org\/abstractslisting\/a\u2010novel\u2010method\u2010to\u2010define\u2010an\u2010electroencephalography\u2010composite\u2010for\u2010the\u2010detection\u2010of\u2010drug\u2010effects\u2010of\u2010next\u2010generation\u2010small\u2010molecules\u2010for\u2010epilepsy[poster available for download fromhttps:\/\/praxismedicines.com\/wp\u2010content\/uploads\/2023\/12\/Hansen_AES2023_qEEG_Poster_Final.pdf]"},{"key":"e_1_2_16_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2017.10.001"},{"key":"e_1_2_16_38_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.115.231712"},{"key":"e_1_2_16_39_1","unstructured":"Human Protein Atlas.CACNG8.2024Available from:https:\/\/www.proteinatlas.org\/ENSG00000142408\u2010CACNG8\/brain"},{"key":"e_1_2_16_40_1","unstructured":"NeuroPace Inc.RNS\u00ae System patient manual for the RNS\u00ae Neurostimulator Model RNS\u2010300M and Model RNS\u2010320.2023Available from:https:\/\/www.neuropace.com\/wp\u2010content\/uploads\/2021\/02\/neuropace\u2010rns\u2010system\u2010patient\u2010manual.pdf. Accessed January 25 2023"},{"key":"e_1_2_16_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02577-y"},{"key":"e_1_2_16_42_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2021-327302"},{"key":"e_1_2_16_43_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awx323"},{"key":"e_1_2_16_44_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan1208"},{"key":"e_1_2_16_45_1","first-page":"1111","article-title":"Generation and characterization of a high affinity anti\u2010human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration","volume":"10","author":"Smith B","year":"2018","journal-title":"MAbs"},{"key":"e_1_2_16_46_1","first-page":"116","article-title":"Pharmacokinetic\u2010pharmacodynamic modelling of the anti\u2010FcRn monoclonal antibody rozanolixizumab","volume":"1","author":"Lledo\u2010Garcia R","year":"2022","journal-title":"Translation"},{"key":"e_1_2_16_47_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.8.5390"},{"key":"e_1_2_16_48_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001134"},{"key":"e_1_2_16_49_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.25439"},{"key":"e_1_2_16_50_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2023.2300155"},{"key":"e_1_2_16_51_1","unstructured":"RozanolixizumabPI.RYSTIGGO (rozanolixizumab\u2010noli). Prescribing information. UCB Pharma.2023."},{"key":"e_1_2_16_52_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011108"},{"key":"e_1_2_16_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00077-7"}],"container-title":["Epilepsia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/epi.18056","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T07:28:41Z","timestamp":1729582121000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/epi.18056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,15]]},"references-count":52,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10.1111\/epi.18056"],"URL":"https:\/\/doi.org\/10.1111\/epi.18056","archive":["Portico"],"relation":{},"ISSN":["0013-9580","1528-1167"],"issn-type":[{"value":"0013-9580","type":"print"},{"value":"1528-1167","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,15]]},"assertion":[{"value":"2024-05-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}